Lurbinectedin is a drug that is used to treat various types of cancer. Anaphylaxis is a severe allergic reaction that can occur in response to the administration of any drug. While there is no specific information available on the risk factors for Lurbinectedin-induced anaphylaxis, it is important to note that any patient can potentially develop an allergic reaction to any medication, including Lurbinectedin. Patients with a history of allergies, especially those with a history of severe allergic reactions, may be at a higher risk of developing anaphylaxis in response to Lurbinectedin or any other medication.
According to the National Center for Biotechnology Information (NCBI), anaphylaxis is a rare but serious side effect of Lurbinectedin [2]. The drug has been associated with a small number of cases of anaphylaxis during clinical trials. Therefore, healthcare providers must monitor patients carefully for any signs of an allergic reaction, such as hives, difficulty breathing, and swelling of the face, lips, tongue, or throat, during and after administration of Lurbinectedin.
It is also important to note that the Centers for Medicare & Medicaid Services (CMS) has identified Lurbinectedin as a high-cost drug [3]. This means that the drug may be more expensive than other treatments, which could limit its availability to some patients.
In conclusion, while there is no specific information available on the risk factors for Lurbinectedin-induced anaphylaxis, patients with a history of allergies, especially those with a history of severe allergic reactions, may be at a higher risk of developing anaphylaxis in response to Lurbinectedin or any other medication. Healthcare providers must monitor patients carefully for any signs of an allergic reaction during and after administration of Lurbinectedin. Additionally, the high cost of Lurbinectedin may limit its availability to some patients.
Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/books/NBK548148/
[3] https://data.cms.gov/sites/default/files/2023-02/Medicare-Part-B-Drug-Dashboard-Manufacturer-Drug_use%20-%20230202.xlsx